SPARC inks pact to sell Priority Review Voucher for $195 million
PRV was granted by the U.S. Food and Drug Administration for the approval of Sezaby indicated for the treatment of neonatal seizures
Sun Pharma Advanced Research Company (SPARC) has entered into a definitive asset purchase agreement to sell its Rare Paediatric Disease Priority Review Voucher (PRV) for $195 million upon the closing of the transaction. PRV was granted by the U.S. Food and Drug Administration (FDA) for the approval of Sezaby indicated for the treatment of neonatal seizures.
The transaction is subject to customary closing conditions, including expiration of the applicable waiting period under the Hart-Scott Rodino (HSR) Antitrust Improvements Act. Stifel acted as the exclusive financial advisor to SPARC with respect to this transaction.
Sun Pharma Advanced Research Company is a clinical stage bio-pharmaceutical company focused on continuously improving standards of care for patients globally, through innovation in therapeutics and delivery.
